| Literature DB >> 30423297 |
Aung Naing1, Jeffrey R Infante2, Kyriakos P Papadopoulos3, Ivan H Chan4, Cong Shen5, Navneet P Ratti4, Bianca Rojo4, Karen A Autio5, Deborah J Wong6, Manish R Patel7, Patrick A Ott8, Gerald S Falchook9, Shubham Pant10, Annie Hung4, Kara L Pekarek4, Victoria Wu4, Matthew Adamow5, Scott McCauley4, John B Mumm4, Phillip Wong5, Peter Van Vlasselaer4, Joseph Leveque4, Nizar M Tannir1, Martin Oft11.
Abstract
Tumor-reactive T cell exhaustion prevents the success of immune therapies. Pegilodecakin activates intratumoral CD8+ T cells in mice and induces objective tumor responses in patients. Here we report that pegilodecakin induces hallmarks of CD8+ T cell immunity in cancer patients, including elevation of interferon-γ and GranzymeB, expansion and activation of intratumoral CD8+ T cells, and proliferation and expansion of LAG-3+ PD-1+ CD8+ T cells. On pegilodecakin, newly expanded T cell clones, undetectable at baseline, become 1%-10% of the total T cell repertoire in the blood. Elevation of interleukin-18, expansion of LAG-3+ PD-1+ T cells and novel T cell clones each correlated with objective tumor responses. Combined pegilodecakin with anti-PD-1 increased the expansion of LAG-3+ PD-1+ CD8+ T cells.Entities:
Keywords: AM0010; CD8(+) T cell; IL-10; PEGylated Interleukin 10; T cell invigoration; Th1; clinical trial; clonal expansion; clonality; pegilodecakin
Mesh：
Substances：
Year: 2018 PMID： 30423297 PMCID： PMC8098754 DOI： 10.1016/j.ccell.2018.10.007
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743